Because patients with PCOS are at particular risk of ovarian hyperstimulation syndrome (OHSS), the gonadotropin-releasing hormone antagonist (GnRH-ant) protocol is preferred as a safer alternative to traditional GnRH-agonist protocols because of the reduced risk of OHSS [6,7]. This evidence concerns the gene GNRH1 and polycystic ovary syndrome.